SCHEMBL13615260

SCHEMBL13615260

CN(C)CCCCNC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
TSHR P16473 1/20 0.48
DNM1 Q05193 3/20 0.40
TDP1 Q9NUW8 1/20 0.38
PRMT3 O60678 1/20 0.36
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
PRMT1 Q99873 1/20 0.36
PRMT8 Q9NR22 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
PAOX Q6QHF9 1/20 0.35
KCNH2 Q12809 1/20 0.35
HRH4 Q9H3N8 2/20 0.35
HRH3 Q9Y5N1 2/20 0.35
SIGMAR1 Q99720 1/20 0.34
KDM4E B2RXH2 1/20 0.33
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14195466 0.98 ALDH1A1 (0.52) ALDH1A1TSHRDNM1TDP1PRMT3
SCHEMBL13792394 0.98 ALDH1A1 (0.52) ALDH1A1TSHRDNM1TDP1PRMT3
SCHEMBL9404552 0.92 TDP1 (0.44) ALDH1A1TSHRDNM1TDP1PRMT3
SCHEMBL2604979 0.81 PRMT3 (0.48) ALDH1A1TSHRTDP1PRMT3CARM1
SCHEMBL12619701 0.81 HRH4 (0.33) HRH4HRH3POLB
SCHEMBL7834390 0.81 HRH4 (0.43) ALDH1A1TSHRCYP2C19HRH4HRH3
SCHEMBL27370492 0.79 HRH4 (0.35) ALDH1A1TSHRHRH4HRH3
Hydrochloric Acid SCHEMBL3176008 0.79 PRMT3 (0.46) ALDH1A1TSHRDNM1TDP1PRMT3
SCHEMBL22851022 0.79 POLB (0.36) ALDH1A1HRH4HRH3KDM4EPOLB
SCHEMBL1276622 0.78 HRH4 (0.45) ALDH1A1CYP2C19HRH4HRH3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11685722-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-06-27 US disclosed
US-11685722-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-06-27 US disclosed
US-20230054854-A1 COMBINATIONS RECURIUM IP HOLDINGS, LLC 2023-02-23 US disclosed
US-11242323-B2 Inhibition of OLIG2 activity Curtana Pharmaceuticals, Inc. (US) 2022-02-08 US disclosed
US-20210139482-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2021-05-13 US disclosed
US-20200407329-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2020-12-31 US disclosed
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685722-B2 Inhibition of Olig2 activity GLI2, ING2, GMFG ALDH1A1 1478/4885TSHR 4810/4885DNM1 2449/4885
US-20210139482-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES MKI67, BRCA1, CCNI ALDH1A1 127/4885TSHR 2461/4885DNM1 1176/4885
US-20230054854-A1 COMBINATIONS WEE2, WEE1, BCL2 ALDH1A1 2291/4885TSHR 3944/4885DNM1 1535/4885
US-11242323-B2 Inhibition of OLIG2 activity POU2F2, ING2, PAX2 ALDH1A1 1801/4885TSHR 4804/4885DNM1 3544/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2121/4885TSHR 3094/4885DNM1 2262/4885
US-20200407329-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG ALDH1A1 1478/4885TSHR 4810/4885DNM1 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.